1. Home
  2. WSHP vs IMA Comparison

WSHP vs IMA Comparison

Compare WSHP & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WSHP

WeShop Holdings Limited Class A Ordinary Shares

N/A

Current Price

$5.50

Market Cap

75.7M

Sector

N/A

ML Signal

N/A

IMA

ImageneBio Inc.

HOLD

Current Price

$6.00

Market Cap

66.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WSHP
IMA
Founded
2021
2019
Country
British Virgin Islands
United States
Employees
20
17
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.7M
66.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WSHP
IMA
Price
$5.50
$6.00
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
$16.00
AVG Volume (30 Days)
48.5K
13.6K
Earning Date
01-01-0001
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.95
$3.94
52 Week High
$250.00
$17.50

Technical Indicators

Market Signals
Indicator
WSHP
IMA
Relative Strength Index (RSI) 40.17 59.07
Support Level $5.05 $5.86
Resistance Level $7.50 $6.06
Average True Range (ATR) 0.54 0.32
MACD 0.07 0.03
Stochastic Oscillator 19.36 95.52

Price Performance

Historical Comparison
WSHP
IMA

About WSHP WeShop Holdings Limited Class A Ordinary Shares

WeShop Holdings Ltd is a community owned social commerce platform offering shoppers shares in the company every time customers make a purchase, recommend a product or refer a new member. WeShop earns revenues from advertising on their platform and commissions on the sales through the platform.

About IMA ImageneBio Inc.

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

Share on Social Networks: